Departments of Pathology.
Oncology, Faculty of Medicine, Menoufia University, Monufia Governorate, Egypt.
Appl Immunohistochem Mol Morphol. 2021 Apr 1;29(4):277-286. doi: 10.1097/PAI.0000000000000877.
Breast cancer (BC) is the most common malignancy in female individuals worldwide. It constitutes about 38.8% of all malignant tumors among Egyptian female individuals. Neuropeptide Y1 receptor (NPY1R) is one of the most abundant peptides in the central and peripheral nervous systems of mammals. It has been found to promote proliferation, vascularization, and stimulate migration in several cell types and tissues and some types of tumor. This the first immunohistochemical study to evaluate the expression of NPY1R in BC and its correlation with clinicopathologic parameters and patient survival. This study included 92 patients with BC. Immunohistochemical staining for NPY1R was done on paraffin-embedded formalin-fixed tissue sections. Statistically significant increases in NPY1R expression was seen in malignant (46/92; 50%) versus non-neoplastic tissue (12/29; 20.7%) (P<0.001). The receiver operating characteristic curve showed that NPY1R is a poor diagnostic test for BC (P<0.001, area under the curve=0.686) in breast tissue. Membranous was the most common pattern of positivity in carcinoma cases (24/46; 52.2%). Statistically significant associations were found between positive NPY1R expression and the presence of metastatic disease (P<0.001), clinical stage (P=0.0003), perineurial invasion (P=0.003), estrogen receptor expression (P=0.004), molecular subtype (P=0.015), Nottingham Prognostic Index risk group (P=0.04), radiotherapy treatment (P=0.01), hormonal treatment (P=0.015), and type of endocrine therapy (P=0.011). Although no significant association was detected between NPY1R-positive and NPY1R-negative cases regarding overall survival and progression-free survival, cases with non-nuclear (membranous+cytoplasmic) expression showed near significantly shorter survival (P=0.063). This study shows that NPY1R was identified in about 50% of malignant BC cases. Its expression correlates with some features of the aggressive disease being associated with metastasis, perineurial invasion, advanced stages, and poor Nottingham Prognostic Index. This suggests a potential prognostic role of NPY1R in BC. Non-nuclear expression of NPY1R seems to be more important in terms of prognosis of BC.
乳腺癌（BC）是全球女性中最常见的恶性肿瘤。它约占埃及女性所有恶性肿瘤的 38.8%。神经肽 Y1 受体（NPY1R）是哺乳动物中枢和外周神经系统中最丰富的肽之一。已发现它可促进几种细胞类型和组织以及某些类型的肿瘤的增殖、血管生成和刺激迁移。这是第一项评估 NPY1R 在 BC 中的表达及其与临床病理参数和患者生存相关性的免疫组织化学研究。本研究纳入了 92 例 BC 患者。对石蜡包埋福尔马林固定组织切片进行 NPY1R 的免疫组织化学染色。与非肿瘤组织（12/29；20.7%）相比，恶性组织中 NPY1R 表达的增加具有统计学意义（46/92；50%）（P<0.001）。受试者工作特征曲线显示，NPY1R 是乳腺组织中 BC 的诊断性测试较差（P<0.001，曲线下面积=0.686）。在癌病例中，膜阳性是最常见的阳性模式（24/46；52.2%）。阳性 NPY1R 表达与转移性疾病（P<0.001）、临床分期（P=0.0003）、神经周浸润（P=0.003）、雌激素受体表达（P=0.004）、分子亚型（P=0.015）、诺丁汉预后指数危险组（P=0.04）、放疗治疗（P=0.01）、激素治疗（P=0.015）和内分泌治疗类型（P=0.011）之间存在统计学显著相关性。尽管在总生存和无进展生存方面，NPY1R 阳性和 NPY1R 阴性病例之间未检测到显著相关性，但非核（膜+细胞质）表达的病例生存时间明显缩短（P=0.063）。本研究表明，NPY1R 在约 50%的恶性 BC 病例中被识别。其表达与侵袭性疾病的某些特征相关，包括转移、神经周浸润、晚期和较差的诺丁汉预后指数。这表明 NPY1R 在 BC 中具有潜在的预后作用。NPY1R 的非核表达在 BC 的预后方面似乎更为重要。
